3 recruiting. 2 Early Phase 1, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 2 | Recruiting 2 |
| Phase 1 | 1 | Recruiting 1 |
Follow Radiotracer: new trials by email Literature Review of Radiotracer trials Research Report on Radiotracer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma Cetuximab (EGFR inhibitor), 18F-NOTA-ABY-030, Positron Emission Tomography (PET) - SCC - Squamous Cell Carcinoma, Radiotracer | Phase 1 | Recruiting | Vanderbilt-Ingram Cancer Center | 25 | 2026-04-24 | 2026-05-11 |
| Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Groups 2, 3 & 4) Dexamethasone (Group 2), Cosyntropin (Group 3), PET/CT Scan with FNP-59 - Radiotracer, Hypertension | Early Phase 1 | Recruiting | Benjamin Viglianti | 24 | 2021-11-01 | 2025-12-05 |
| Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Group 1) FNP-59 - Radiotracer, Hypertension | Early Phase 1 | Recruiting | Benjamin Viglianti | 6 | 2021-01-18 | 2025-12-05 |
Hypertension (2) · Carcinoma, Squamous Cell (1) · Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
Cardiovascular Diseases (2) · Vascular Diseases (2) · Carcinoma (1) · Head and Neck Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Glandular and Epithelial (1) · Neoplasms, Squamous Cell (1)
Cetuximab (1) · Cosyntropin (1) · Dexamethasone (1) · Magnetic Resonance Spectroscopy (1)
Benjamin Viglianti (2) · Vanderbilt-Ingram Cancer Center (1)
United States (3)
Ben Viglianti, M.D, Ph.D. (1) · Benjamin L Viglianti, M.D, Ph.D. (1) · Eben Rosenthal, MD (1)